Rani Therapeutics Holdings, Inc. Class A RANI 深 滬
等待開盤 02-05 09:30:00 美东时间
1.19
-0.040
-3.25%
華盛通- 最 高1.26
- 今 開1.26
- 成交量 111.17万股
- 最 低 1.15
- 昨 收 1.23
- 總市值 3994.87万
- 52周最高 3.87
- 市盈率 靜 --
- 換手率 3.31%
- 52周最低 0.387
- 委 比 -95.80%
- 總股本 3357.03万
- 歷史最高 36.27
- 量 比 0.95
- 振 幅 8.94%
- 歷史最低 0.387
- 每 手 1
- 風險率 0.54%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
Rani Therapeutics Initiated Phase 1 Trial of RT-114, an Orally Administered Ranipill Capsule Containing GLP-1/GLP-2 Dual Agonist, PG-102, for Obesity
PG-102 is a fc-fusion protein conjugated GLP-1/GLP-2 dual agonist in development by ProGen Co., Ltd. ("ProGen"). ProGen recently announced preclinical and clinical data, at the 2025 European Association for the Study of
01-08 20:14
Rani Therapeutics finalizes governance and capital structure changes
Rani Therapeutics Holdings ( ($RANI) ) has shared an update. On October 16, 202...
01-03 06:48
Rani Therapeutics to Participate in the Evercore Healthcare Conference
Rani Therapeutics' management will participate in the 8thAnnual Evercore Healthcare Conference on December 3, 2025, in Coral Gables, FL. CEO Talat Imran and CFO Svai Sanford will engage in Fireside Chat and 1x1 meetings. Interested parties can access the live webcast via the company's Investor Relations website, with a replay available post-presentation. Rani Therapeutics specializes in oral delivery of biologics using its RaniPill® capsule techn...
2025-11-24 21:05
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers enGene Holdings (NASDAQ:ENGN) stock moved upwards by 3.5% to $7.12 dur...
2025-11-19 05:06
Rani Therapeutics Hldgs Q3 EPS $(0.12) Beats $(0.15) Estimate
Cash, cash equivalents and marketable securities as of September 30, 2025 totaled $4.1 million, compared to $27.6 million for the year ended December 31, 2024. Rani expects its cash, and cash equivalents, including the
2025-11-07 05:57
Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update
Rani Therapeutics announced a $1.085 billion collaboration with Chugai Pharmaceutical to develop oral therapies using its RaniPill® platform. The company also completed a $60.3 million private placement led by Samsara BioCapital and appointed Abraham Bassan and Vasudev Bailey, Ph.D., to its Board of Directors. With enhanced cash runway into 2028, Rani plans to initiate a Phase 1 clinical trial for its obesity treatment RT-114 by year-end.
2025-11-06 21:30
期权扫描 | 挑战AI泡沫？英伟达、Palantir期权多空分歧巨大；AMD绩后大跌近5%，期权成交翻倍
“大空头”挑战AI泡沫，同时买入辉瑞、哈里伯顿看涨期权；英伟达、Palantir期权多空分歧巨大；AMD绩后大跌近5%，期权成交翻倍>>
2025-11-05 17:05
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Cabaletta Bio (NASDAQ:CABA) shares rose 36.6% to $3.38 during Friday's...
2025-11-01 01:06
Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025
SAN JOSE, Calif., Oct. 30, 2025 – Rani Therapeutics Holding, Inc. announced that it will present preclinical data on its RaniPill® capsule at ObesityWeek® 2025 on November 4-7, 2025, in Atlanta, Georgia. The presentation titled "Oral Semaglutide (RT-116) in Dogs is Bioequivalent to SC Injections and Elicits Similar Weight Loss" will be part of a poster session on November 6, 2025, from 2:30 pm – 3:30 pm E.T., featuring Rani's oral delivery platfo...
2025-10-30 12:00
